Drug Trial Radar · NCT06473948
To Assess the Effects of Single Dose of JMKX001899 on QTc Interval in Healthy Subjects
Last checked: Nov 20, 2026Latest source record: Jun 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
27
Planned (sponsor's estimate)
Start
Jul 10, 2024
Primary completion
Sep 24, 2024
Study completion Feb 27, 2025
Sponsor
- Lead sponsor
- JemincareIndustry
- Sponsor type
- Industry
- First posted
- Jun 25, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Basic science
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Study to assess the effect of JMKX001899 on QTc interval in healthy volunteers
Conditions
- Solid Tumor, Adult
Interventions
JMKX001899Drug
Participants will receive JMKX001899 500mg tablet, orally once on Day 1
JMKX001899Drug
Participants will receive JMKX001899 750mg tablet, orally once on Day 1
JMKX001899Drug
Participants will receive JMKX001899 1000mg tablet, orally once on Day 1
PlaceboDrug
Participants will receive JMKX001899 matching placebo, tablet, orally once on Day 1
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the effect of a single dose of JMKX001899 on the change in time-matched QTc intervals compared with placeboTime frame: 48 hours
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.